Seattle Genetics and Dr. Clay Siegall Develop Effective Cancer Therapies

Biotechnology company Seattle Genetics is known for developing and commercializing effective cancer treatments using empowered monoclonal antibody-based therapies. The company has its headquarters in Bothell, Washington and is an industry leader in the use of innovative antibody-drug conjugates technology. Their ADC conjugates technology are able to harness the ability of monoclonal antibodies to directly deliver cell-killing agents to cancer cells. ADCs kills cancer cells, spares non-targeted cells and reduces traditional chemotherapy’s toxic effects. Those drugs are used in 60 countries.

Founded in 1997, Seattle Genetics is a company where scientific excellence, integrity, teamwork, rigorous research and innovation are highly prized. The entire staff is passionate about and driven to help people suffering with cancer. Their collaborative efforts have led to the development ADCs and of a number of technologies in its product pipeline that show great promise in the treatment of cancer. The ultimate goal of the staff of Seattle Genetics is to improve the outcomes for cancer patients. Seattle Genetics’ leadership encourages intellectual curiosity and an entrepreneurial spirit that has led to many breakthrough therapies.

The co-founder, president and CEO of Seattle Genetics is Dr. Clay Siegall. Dr. Siegall has been involved in cancer research for over three decades. Prior to co-founding Seattle Genetics he worked with Bristol-Myers Squibb Pharmaceutical Research Institute, the National Institutes of Health and the National Cancer Institute. Dr. Siegall’s ongoing work and innovative leadership has created the drug development practices that have pushed the company into the forefront of effective cancer treatments with the FDA approval of ADCETRIS. The drug now helps cancer patients worldwide.

Although Dr. Siegall is a scientist by training, he has been very instrumental in raising funds for Seattle Genetics. He has entered into multiple lucrative strategic licenses with Pfizer, AbbVie, GlaxoSmithKline and Genentech. These agreements have generated in excess of $325 million for Seattle Genetics from its ADC technology. Dr. Siegall also raised over $1.2 billion from public and private funding sources for the facility. His work has helped to make Seattle Genetics a global brand and led to Dr. Siegall being voted Entrepreneur of the Year in 2012.